REGENXBIO Inc. (NASDAQ:RGNX) Receives $35.27 Consensus Target Price from Analysts

REGENXBIO Inc. (NASDAQ:RGNX) has been assigned an average recommendation of “Moderate Buy” from the twelve analysts that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and eleven have issued a buy recommendation on the company. The average 1 year target price among analysts that have covered the stock in the last year is $35.27.

A number of equities research analysts have commented on RGNX shares. Morgan Stanley reissued an “overweight” rating and set a $22.00 price objective on shares of REGENXBIO in a report on Friday, November 15th. HC Wainwright decreased their price target on shares of REGENXBIO from $40.00 to $36.00 and set a “buy” rating on the stock in a research note on Thursday, November 21st. StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, September 20th. Raymond James reaffirmed an “outperform” rating and set a $18.00 price objective on shares of REGENXBIO in a report on Thursday, October 10th. Finally, Chardan Capital reissued a “buy” rating and issued a $52.00 target price on shares of REGENXBIO in a research note on Wednesday, November 20th.

Institutional Investors Weigh In On REGENXBIO

Institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC boosted its holdings in REGENXBIO by 273.1% during the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock worth $27,000 after buying an additional 2,510 shares during the last quarter. FMR LLC raised its position in shares of REGENXBIO by 166.8% in the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 1,656 shares during the period. nVerses Capital LLC raised its position in shares of REGENXBIO by 183.3% in the 3rd quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 2,200 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in REGENXBIO by 64.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 3,720 shares during the last quarter. Finally, Arizona State Retirement System grew its holdings in REGENXBIO by 20.6% during the second quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company’s stock valued at $137,000 after purchasing an additional 1,997 shares during the period. 88.08% of the stock is owned by institutional investors and hedge funds.

REGENXBIO Stock Performance

Shares of RGNX stock opened at $8.29 on Monday. REGENXBIO has a 52 week low of $7.14 and a 52 week high of $28.80. The stock has a market capitalization of $410.73 million, a PE ratio of -1.65 and a beta of 1.28. The stock’s fifty day moving average is $9.03 and its 200-day moving average is $10.71.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.